Great analysis first off. It further enhances my overall opinion on the complete situation moving forward. I have stated in the past and still believe that the Aspire agreement is a contingency plan if the secondary end points are not met in the Prurisol outcome. I believe the deal for B-OM is ready but not inked. I believe the same company on the ready has first right to purchase IP as a whole if Prurisol results are to their standard.
The future is set but it completely depends on the Prurisol results. Exceptional P results and we have a buyout. If results are not to other Pharmaceutical standards then we have a partnership for one indication (B-OM) and then IP works to get other B indications partnered and further progress P and K as they see fit.
News 
Market Data 
Discover 
